Use of a Conformational Switching Aptamer for Rapid and Specific Ex Vivo Identification of Central Nervous System Lymphoma in a Xenograft Model
Improved tools for providing specific intraoperative diagnoses could improve patient care. In neurosurgery, intraoperatively differentiating non-operative lesions such as CNS B-cell lymphoma from operative lesions can be challenging, often necessitating immunohistochemical (IHC) procedures which require up to 24-48 hours. Here, we evaluate the feasibility of generating rapid ex vivo specific labeling using a novel lymphoma-specific fluorescent switchable aptamer. Our B-cell lymphoma-specific switchable aptamer produced only low-level fluorescence in its unbound conformation and generated an 8-fold increase in fluorescence once bound to its target on CD20-positive lymphoma cells. The aptamer demonstrated strong binding to B-cell lymphoma cells within 15 minutes of incubation as observed by flow cytometry. We applied the switchable aptamer to ex vivo xenograft tissue harboring B-cell lymphoma and astrocytoma, and within one hour specific visual identification of lymphoma was routinely possible. In this proof-of-concept study in human cell culture and orthotopic xenografts, we conclude that a fluorescent switchable aptamer can provide rapid and specific labeling of B-cell lymphoma, and that developing aptamer-based labeling approaches could simplify tissue staining and drastically reduce time to histopathological diagnoses compared with IHC-based methods. We propose that switchable aptamers could enhance expeditious, accurate intraoperative decision-making.
- Author (aut): Georges, Joseph F.
- Author (aut): Liu, Xiaowei
- Author (aut): Eschbacher, Jennifer
- Author (aut): Nichols, Joshua
- Author (aut): Mooney, Michael A.
- Author (aut): Joy, Anna
- Author (aut): Spetzler, Robert F.
- Author (aut): Feuerstein, Burt G.
- Author (aut): Preul, Mark C.
- Author (aut): Anderson, Trent
- Author (aut): Yan, Hao
- Author (aut): Nakaji, Peter
- Contributor (ctb): ASU Biodesign Center Immunotherapy, Vaccines and Virotherapy
- Contributor (ctb): Biodesign Institute